Events and News

Research Collaboration between XtalPi Inc and Acerand Therapeutics to develop potential novel anti-cancer therapies using High-precision Physics-based model and Machine Learning

XtalPi, a leading AI drug discovery company, announces a research collaboration with Acerand Therapeutics, a biotechnology company specialized in developing best-in-class and or first-in-class drugs. The partnership will leverage XtalPi's highly accurate physics-based models and machine learning models to develop potential novel chemical entities for a cancer target.

XtalPi and Sedec Therapeutics announces the collaboration of novel therapeutics development against autoimmune diseases

XtalPi and Sedec have recently reached an agreement to develop novel small-molecule therapeutics targeting STAT3 palmitoylation pathway for auto immune disorder diseases treatment.

XtalPi Invests in Novel Target Discovery Biotech PhoreMost in Oversubscribed Series B Financing

CAMBRIDGE, Mass., March 23, 2021 -- XtalPi, an artificial intelligence (AI) drug discovery and development company, is pleased to announce its investment in the Series B financing of PhoreMost, a UK-based biopharmaceutical company dedicated to Drugging the Undruggable disease targets. The investment round totaled $46 million and was led by BGF, with participation from XtalPi and a panel of new and existing investors. XtalPi Chief Strategy Officer (CSO) Dr. Alan Jiang will join PhoreMost Board of Directors.

AI-biotech XtalPi Partners with Singleron to Discover Novel Targeted Therapies for GI Cancers

XtalPi and Singleron will simultaneously conduct target validation and drug discovery, pursuing multiple promising targets and research paths in parallel.

XtalPi and PhoreMost Sign AI-based Pharmaceutical Drug Discovery Collaboration Agreement

XtalPi and PhoreMost sign drug discovery collaboration to discover novel inhibitors of "undruggable" targets

XtalPi Announces Strategic Collaboration with Porton

Combining AI Algorithms with Targeted Experiments to Solve Bottleneck Challenges in Drug Development

XtalPi Research on SARS-CoV-2 (Updated)

XtalPi team shares the timeline and preliminary results on their research of the new coronavirus.

World's Top 20 AI Drug Development Companies

XtalPi named as one of World's Top 20 AI Drug Development Companies

XtalPi Announces the Closing of $46 Million Series B-1 Extension

to support XtalPi’s continuous market growth and expand the application of its technology into new areas of pharmaceutical research.

How Quantum Physics and AI is Disrupting Drug Discovery & Development

Case study on how XtalPi is helping pfizer scientists predict and optimize the crystalline forms of drug candidates.

XtalPi Inc. Announces Strategic Research Collaboration with Pfizer Inc

to Develop Artificial Intelligence-Powered Molecular Modeling Technology for Drug Discovery